ABSTRACT
INTRODUCTION
Obesity has been associated with increased risk of several types of cancer, including breast and colon cancer (1) , but the relationship between obesity and prostate cancer is less clear. Giovannucci et al. reported a relationship between increased risk of fatal prostate cancer and taller height and higher Body Mass Index (BMI) using results from the Health Professionals Follow-up Study (2) . Findings from the Cancer Prevention Study II, another large prospective cohort study in the U.S., suggested that obesity is positively associated with prostate cancer mortality (3) . Recent study results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database found that obesity is a risk factor for aggressive prostate cancer regardless of race (4) . On the other hand, a cross-sectional evaluation of 1,814 prostate cancer patients in Germany suggested that obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy (5) . Similarly, a clinical cohort of 2,687 patients who underwent treatment for low and intermediate grade of prostate cancer found no association between BMI and biochemical failure after at least of two-year follow-up (6) . Another population-based cohort study of 10,564 men in Sweden suggested that height is associated with total and non-aggressive prostate cancer risk, but not aggressive cancer (7) . BMI was not associated with either aggressive or non-aggressive prostate cancer. Review of published studies concluded that BMI is not associated with prostate cancer overall, but may be associated with more aggressive disease (8) (9) (10) (11) .
A proposed mechanism for the obesity and prostate cancer aggressiveness association involves testosterone, estrogen and the insulin like growth factor I (IGF-I) axis.
Specifically, men with excess central adiposity have lower testosterone levels, which may be associated with higher stage and grade of prostate cancer at the time of diagnosis (12, 13) . Additionally, circulating IGF-I, a potential prostate cancer mitogen, is elevated among men with hyperinsulinemia, which is common among obese men (14) .
The inconsistent study findings on prostate cancer and obesity may be explained, at least in part, by the high prevalence of latent prostate cancer and the widespread use of prostate-specific antigen (PSA) for screening for prostate cancer in the U.S. (15) . A closer look at the data reveals that the majority of the evidence for a relationship between obesity and advanced prostate cancer is based on CA populations, whereas a greater burden of prostate cancer is seen in AAs. Age-adjusted prostate cancer incidence and mortality rates for AA men are approximately 60% and 140% higher, respectively, than rates for CAs (16) . Therefore, the purpose of this study was to evaluate the relationship between obesity, measured using BMI and waist-to-hip ratio (WHR), and prostate cancer aggressiveness classified based on Gleason grade, clinical stage, and PSA at diagnosis in a population-based study of similar numbers of incident prostate cancer cases in African and CAs.
MATERIALS AND METHODS
Data from the North Carolina -Louisiana Prostate Cancer Project (PCaP), a populationbased cross-sectional study of incident prostate cancer in two southern states in the U.S., was analyzed (17) . Research subjects were identified using rapid case ascertainment to identify newly diagnosed prostate cancer cases in an unbiased fashion.
Analysis of the relationship between obesity and prostate cancer aggressiveness was based on research data collected from research subjects who were recruited from July Residents of the North Carolina and Louisiana study catchment areas with a first diagnosis of histologically confirmed adenocarcinoma of the prostate on or after July 1, 2004 were eligible to participate in the PCaP study if they were 40-79 years of age at diagnosis, could complete the study interview in English, did not live in an institution (nursing home), were not cognitively impaired or in a severely debilitated physical state, and were not under the influence of alcohol, severely medicated, or apparently Weight (in kg), height, and waist and hip circumferences (in cm) were measured at the time of interview (median 118.5 days after prostate cancer diagnosis) by PCaP nurses using standardized instruments. Participants also were asked their usual weight and height at age 25 and their weight one year prior to the research study visit. Height and weight measurements taken at the time of interview and self-reported weight one year prior to the study visit were used to calculate two separate measures of BMI. Waist and hip circumferences measured at the time of interview were used to calculate the WHR.
PCaP nurses administered a series of structured questionnaires that solicited information on background characteristics, occupation, family history of prostate cancer, comorbid conditions, health care access, prostate cancer diagnosis and screening history, diet, supplement use, physical activity and other characteristics. Participants also were asked whether they or their doctor had decided which type of treatment was best for them and whether the treatment had started. Medical records related to prostate cancer diagnosis, and staging were requested from the diagnosing physician of consenting participants and abstracted to obtain clinical stage, Gleason grade and PSA at the time of diagnosis, in addition to other information. Approximately 10% of medical records were selected at random and abstracted by a second staff member to assess consistency among abstractors (18) .
Complete prostate cancer aggressiveness data were available for 2,173 eligible research subjects. Standing height of 19 research subjects could not be measured because of their physical condition (could not stand) at interview so they were excluded from further analysis because BMI could not be calculated. Two additional research research subjects (74.6%) were categorized in the same weight category based on the self-reported weight and weight measured at time of interview; and 15 research subjects (0.7%) were categorized more than 1 weight category difference. Because the number of research subjects who were categorized as underweight was small (8 based on BMI 1-year before diagnosis and 19-based on post-diagnosis measurement), these research subjects were excluded from multivariate logistic regression models examining the association between BMI and prostate cancer aggressiveness. Results were reported based on the BMIs calculated from both self-reported weight and interviewer measured weight. Waist and hip circumferences were not available for 2 additional research subjects who had BMI data. Therefore, 2,130 research subjects were included in the modeling of WHR and prostate cancer aggressiveness. WHR were categorized into 3 categories, where the reference category was defined as 0.90 or less using the World Health Organization's definition for metabolic syndrome for men (19) . Those research subjects who had a WHR greater than 0.98 (upper tertile) were categorized as obese.
Cases were classified using Gleason grade, clinical stage, and PSA at diagnosis as 1) high aggressive (Gleason sum >=8, or PSA >20 ng/ml, or Gleason sum >=7 and clinical stage T3-T4), 2) low aggressive (Gleason sum <7 and clinical stage T1-T2 and PSA <10 ng/ml), or 3) intermediate aggressive (all other cases) (17) . Chi-square tests and student's T-test were used to test for significant differences in demographic characteristics between races (α = .05). Multivariate logistic regression adjusting for age at diagnosis, education level, study site, smoking status, first degree family history of prostate cancer (yes/no), previous prostate cancer screening history (whether research (22, 23) , height, and type of prostate cancer treatment received were added to the model but did not impact the effect estimates (< 10%) and were removed. Tests for interaction between race and BMI and WHR using continuous measures (both self-reported 12-month prior to diagnosis and measured at time of home interview after diagnosis) were conducted. Because the focus of this study was to examine the difference between races regarding obesity and prostate cancer aggressiveness, models were first presented pooled and stratified by race and then examined further using normal weight CAs as the reference group to examine the joint effect of race and obesity. Models also were evaluated after stratifying by prostate cancer screening history. Prostate cancer screening history did not appear to be an effect modifier. P-values < 0.05 were considered statistically significant.
RESULTS

Incident prostate cancer cases included 555 AAs and 563 CAs from Louisiana and 494
AAs and 520 CAs from North Carolina (Table 1) . Average age at diagnosis was significantly higher for CAs compared to AAs (64.2 years and 61.8 years, respectively).
Average height and BMI measured at interview were similar between CAs and AAs.
However, AAs were more likely to be classified as obese or severely obese (43.9% versus 37.9% based on self-reported and 39.0% vs. 37.6% measured at time of interview). In contrast, AAs had a slightly smaller mean WHR and were more likely to have WHR less than 0.90 compared to CAs. In logistic regression models adjusted for race, obese and severely obese were statistically significantly associated with high aggressive prostate cancer. The odds ratios were similar, regardless of whether the BMI was calculated based self-reported pre-prostate cancer diagnosis body weight or body weight measured at the time of study interview after diagnosis. The odds ratios for high aggressive prostate cancer among obese were 1.48 (95%CI = 1.02, 2.16) and 1.54 (1.07, 2.21), and the odds ratios among severely obese were 1.98 (95%CI= 1.31, 2.97) and 1.73 (95%CI = 1.14, 2.61) for self-reported and interviewer-measured BMI, respectively. Waist-to-hip ratio greater than 0.98 also was significantly associated with high aggressive prostate cancer (OR = 1.42, 95%CI = 1.00, 2.00) when compared to those whose waist-to-hip ratio was less than 0.90.
Test for interaction between race and BMI using continuous measures (both self- In order to further quantify the effects of race and obesity relative to a common referent group, normal BMI CAs were used as the reference group to examine the relationship between BMI and prostate cancer aggressiveness. Similar to the results observed in Table 2 
DISCUSSION
Associations between measures of obesity and prostate cancer aggressiveness were examined using data from a population-based study of incident prostate cancer among African and CAs in Louisiana and North Carolina. A strong association between BMI and prostate cancer aggressiveness with a positive dose-response relationship was evident. WHR greater than 0.98 also was positively associated with high aggressive prostate cancer. The stratified results suggest the risk of high aggressive prostate cancer among obese and severely obese CAs is more than double that of normal weight CAs. AAs were more likely to have aggressive prostate cancer, even with normal BMI, when compared to normal weight CAs. Although the trend for increased BMI and prostate cancer aggressiveness was not as clear among AAs as CAs, obese and severely obese AAs appear to be diagnosed with more aggressive prostate cancer than leaner individuals. A stronger association was found using self-reported body weight prior to cancer diagnosis compared to body weight measured by a PCaP nurse after a prostate cancer diagnosis among Caucasians; but the post-diagnosis measurements were greater among AAs. The difference observed could be attributed to weight loss as the result of prostate cancer, treatment of prostate cancer, recall bias, differences in weight sensitivity, lack of knowledge of weight, or all of above. Nevertheless, obesity measured by either pre-or post-diagnosis body weight showed significant association with prostate cancer aggressiveness.
Several studies have reported a positive association between obesity in adulthood and advanced prostate cancer and prostate cancer mortality (8), but others observed inverse associations between obesity early in life and aggressive disease (24, 25) . The weight of this evidence is based on studies where 80% or more of these research subjects were CAs (9, 26, 27) . Most studies examining obesity and prostate cancer have included race as a confounder if AAs were included in the studies (28) (29) (30) (31) (32) .
Recently, analysis of the Shared Equal Access Regional Cancer Hospital (SEARCH) database (662 AA and 753 CA prostate cancer patients choosing radical prostatectomy)
found that obesity was associated with greater risk of recurrence among both African and CAs (4) . Authors conducted the analysis stratified by race and concluded that obesity was a risk factor for aggressive prostate cancer regardless of race (33, 34) .
Similar to these reports, the analysis reported herein took advantage of a large sample size of AAs to examine the association between obesity and prostate cancer aggressiveness by race individually and jointly.
Unlike the report of study of the SEARCH database, this study found that the association between obesity and aggressiveness appeared to be stronger among CAs.
AAs have the highest incidence and mortality from prostate cancer in the world. This study was able to capture the elevated risk of high aggressive cancer of African compared to CAs even when comparing normal weight AAs to normal weight CAs.
Because of elevated risk of aggressive prostate cancer in even normal weight AAs, the effect of obesity on prostate cancer aggressiveness may be partially masked when using normal weight AAs as the reference group. However, the picture was clearer when normal weight CAs were used as the reference group to evaluate the association between obesity and prostate cancer aggressiveness. Being obese or severely obese In order to explain the different patterns observed between races, the first hypothesis was that the risk of high aggressive prostate cancer differed between races because CAs received more frequent care and screening. More frequent screening may lead to earlier detection. Therefore, the cancer was more likely to reflect a rapidly proliferating cancer in CAs when diagnosed with aggressive cancer. On the other hand, AAs presenting with aggressive disease were more likely to have a later diagnosis since they had more time to reach an aggressive state prior to diagnosis. To control for indicators that might capture differences in access to care, such as having had medical visits in the year prior to diagnosis, prostate cancer screening history was included as a covariate. CAs had been screened for PSA more often than AAs (71.0 vs. 45.6%).
However, adjusting for screening history and screening frequency did not impact risk of aggressive prostate cancer related to obesity.
Another possible explanation of racial differences in prostate cancer aggressiveness is that prostate cancer was more difficult to detect among obese men, which delays diagnosis (8) . Greater prostate volumes among obese men may modify the association between BMI or WHR and prostate cancer. Obesity-related prostate enlargement has been reported to obscure the association between BMI and prostate cancer (35) . Obese men compared to lean men have lower likelihood of capturing prostate tissue upon needle biopsy, increased false negative rate upon rectal examination and lower PSA values (36) . Biased treatment by race might explain the difference if less effort is made to conduct a thorough examination for prostate cancer in AAs, or if AAs who are obese are more obese than obese CAs. If the latter were true, and false negatives were related to the amount of adipose tissue present, the criterion, such as BMI and WHR, used would be too crude to detect such an effect. More sophisticated technology, such as Dual Energy X-Ray Absorptometry (DEXA), to quantify body fatness may be needed, which was beyond the scope of PCaP. 
Inherent differences in stature by race have led to arguments that different BMI cutoffs should be used for different races (37) . Other studies have reported that AA men on average were taller than other racial/ethnic groups, which raises the question of whether their higher BMI is less predictive than when BMI is used in populations of shorter men.
A weak positive relationship between height and advanced, but not clinically localized, prostate cancer has been described in some populations (2, 9, 10, 38-40), although in most cases the relationship found was independent of obesity. However, height was not associated with aggressiveness among African or CAs in the PCaP study population.
Given that a racial difference remains after consideration of the above factors, another hypothesis is that prostate cancer aggressiveness differs between African and CAs due to genetic variants or gene-environment interactions that differ by race. Specifically, racial differences in the type and prevalence of polymorphisms within genes or regulatory elements related to pathways involved in obesity and prostate cancer, such as testosterone and estrogen metabolism, and IGF-I axis genes, may offer a partial explanation.
This study has certain limitations. First, prostate cancer aggressiveness was determined based on the clinical characteristics of the disease at the time of diagnosis. Significantly higher proportion of CAs had higher education, higher household income, and received more frequent prostate cancer screening than AAs in PCaP. Consequently, the elevated PSA, Gleason score, and clinical stage, which were used to determine cancer aggressiveness, might result from later diagnosis among AAs. PCaP has not yet collected information regarding biochemical progression-free, disease-free, or overall survival of the research subjects. Efforts to collect outcome information are underway in North Carolina and will start soon in Louisiana. Secondly, neither BMI derived from the self-reported body weight prior to cancer diagnosis nor the interviewer-measured weight after cancer diagnosis were perfect to assess the association between obesity and cancer aggressiveness. The former suffered from the inaccuracy of recalled body weight 12 months prior to cancer diagnosis and the latter was prone to weight loss as the result of cancer or treatment. Therefore, the association between BMI from both 
